Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1627 1642 1644 1671
This examiner grants 58% of resolved cases
Alyssa Rae Stonebraker is a patent examiner in Tech Center 1600 and Art Unit 1627. She has 107 resolved cases. The allowance rate is 57.9 percent. The median days to allowance is 1254. This 1254 days figure provides a timeline for applicants to consider during prosecution. The 107 resolved cases offer a basis for these statistics. This data is specific to her work in Art Unit 1627.
The interview lift for this examiner is 50.1 percent. This lift indicates that the allowance rate changes when an interview is conducted. Practitioners can use this information to decide whether to request an interview. The 57.9 percent allowance rate is the baseline for applications assigned to her. Direct communication is a strategy that relates to the 50.1 percent lift. These figures from Tech Center 1600 help in planning prosecution steps. The 1254 days median is a factor in managing expectations for patent pendency.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16477505 | VALIDATION OF NEOEPITOPE-BASED TREATMENT | Non-Final OA | NANT HOLDINGS IP, LLC |
| 17075238 | OVERLOAD AND ELUTE CHROMATOGRAPHY | Final Rejection | Genentech, Inc. |
| 17762215 | METHODS FOR TREATING METASTATIC TRIPLE NEGATIVE BREAST CANCER WITH ANTI-PD-1 ANTIBODIES | Final Rejection | Merck Sharp & Dohme LLC |
| 18497352 | METHODS OF TREATING CANCER WITH A COMBINATION OF ADOPTIVE CELL THERAPY AND A TARGETED IMMUNOCYTOKINE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18133288 | COMPOSITIONS AND METHODS FOR UNIVERSAL TUMOR CELL KILLING | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18247226 | COMBINATION OF ANTIBODIES FOR TREATING CANCER WITH REDUCED CYTOKINE RELEASE SYNDROME | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17612204 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17260428 | DETERMINING RESPONDERS TO INFLAMMATION TREATMENT | Non-Final OA | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED |
| 17281025 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Final Rejection | NORTH CAROLINA STATE UNIVERSITY |
| 17435159 | ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANTS | Non-Final OA | Cedars-Sinai Medical Center |
| 18673083 | TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY | Final Rejection | Iovance Biotherapeutics, Inc. |
| 17767398 | CANCER COMBINATION TREATMENTS USING ANTI-STAT3 NUCLEIC ACID CONJUGATES | Non-Final OA | CITY OF HOPE |
| 18258071 | TNF ALPHA AND NGF ANTIBODIES FOR VETERINARY USE | Non-Final OA | Elanco US, Inc. |
| 18025349 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Non-Final OA | SEAGEN INC. |
| 18004618 | COMPOSITIONS COMPRISING ANTIBODIES TO HUMAN IDO-2 | Final Rejection | Lankenau Institute for Medical Research |
| 18489627 | NOVEL ANTI-TPBG ANTIBODY AND ANTIBODY-DRUG-CONJUGATES BASED THEREON, THERAPEUTIC METHODS AND USES THEREOF | Non-Final OA | Tubulis GmbH |
| 18549446 | Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof | Final Rejection | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. |
| 18084739 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | Non-Final OA | IntoCell, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy